

2019 Future of Acromegaly R&D Pipeline Drugs and Companies- Analysis of Global Acromegaly Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2A120E4A4C0EN.html>

Date: January 2019

Pages: 65

Price: US\$ 2,199.00 (Single User License)

ID: 2A120E4A4C0EN

Abstracts

The global demand for Acromegaly treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Acromegaly pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Acromegaly pipeline companies from advancing their products into Phase 3 or Phase 4.

Acromegaly Report Description

The H1 2019 pipeline review report on Acromegaly pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Acromegaly pipeline compounds.

The Acromegaly pipeline guide presents information on all active drugs currently being developed for Acromegaly. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Acromegaly pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Acromegaly drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Acromegaly product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Acromegaly pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Acromegaly pipeline report includes

An overview of Acromegaly disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Acromegaly pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Acromegaly pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Acromegaly pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL ACROMEGALY PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Acromegaly Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Acromegaly pipeline, H1- 2019
- 3.5 Mechanism of Action wise Acromegaly Pipeline Candidates

4. AMRYT PHARMA PLC ACROMEGALY PIPELINE DETAILS

- 4.1 Amryt Pharma plc Business Profile
- 4.2 Amryt Pharma plc Acromegaly Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. ANTISENSE THERAPEUTICS LTD ACROMEGALY PIPELINE DETAILS

- 5.1 Antisense Therapeutics Ltd Business Profile
- 5.2 Antisense Therapeutics Ltd Acromegaly Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. AQUESTIVE THERAPEUTICS INC ACROMEGALY PIPELINE DETAILS

- 6.1 Aquestive Therapeutics Inc Business Profile
- 6.2 Aquestive Therapeutics Inc Acromegaly Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. AURITEC PHARMACEUTICALS INC ACROMEGALY PIPELINE DETAILS

- 7.1 Auritec Pharmaceuticals Inc Business Profile
- 7.2 Auritec Pharmaceuticals Inc Acromegaly Drug Details
 - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. CAMURUS AB ACROMEGALY PIPELINE DETAILS

- 8.1 Camurus AB Business Profile
- 8.2 Camurus AB Acromegaly Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. CHIASMA INC ACROMEGALY PIPELINE DETAILS

- 9.1 Chiasma Inc Business Profile
- 9.2 Chiasma Inc Acromegaly Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. CRINETICS PHARMACEUTICALS INC ACROMEGALY PIPELINE DETAILS

- 10.1 Crinetics Pharmaceuticals Inc Business Profile
- 10.2 Crinetics Pharmaceuticals Inc Acromegaly Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. DAUNTLESS PHARMACEUTICALS INC ACROMEGALY PIPELINE DETAILS

- 11.1 Dauntless Pharmaceuticals Inc Business Profile
- 11.2 Dauntless Pharmaceuticals Inc Acromegaly Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. DEXTECH MEDICAL AB ACROMEGALY PIPELINE DETAILS

12.1 DexTech Medical AB Business Profile

12.2 DexTech Medical AB Acromegaly Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. ENESI PHARMA LTD ACROMEGALY PIPELINE DETAILS

13.1 Enesi Pharma Ltd Business Profile

13.2 Enesi Pharma Ltd Acromegaly Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. FORESEE PHARMACEUTICALS CO LTD ACROMEGALY PIPELINE DETAILS

14.1 Foresee Pharmaceuticals Co Ltd Business Profile

14.2 Foresee Pharmaceuticals Co Ltd Acromegaly Drug Details

14.2.1 Drug Snapshot

14.2.1.1 Originator

14.2.1.2 Collaborator/Co-Developer

14.2.1.3 Route of Administration

14.2.1.4 Orphan Drug/Fast Track/Special Designation

14.2.1.5 Area

14.2.1.6 Type of Molecular Entity

14.3 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15. GENESCIENCE PHARMACEUTICALS CO LTD ACROMEGALY PIPELINE DETAILS

15.1 GeneScience Pharmaceuticals Co Ltd Business Profile

15.2 GeneScience Pharmaceuticals Co Ltd Acromegaly Drug Details

15.2.1 Drug Snapshot

15.2.1.1 Originator

15.2.1.2 Collaborator/Co-Developer

15.2.1.3 Route of Administration

15.2.1.4 Orphan Drug/Fast Track/Special Designation

15.2.1.5 Area

15.2.1.6 Type of Molecular Entity

15.3 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16. GLYTECH INC ACROMEGALY PIPELINE DETAILS

16.1 GlyTech Inc Business Profile

16.2 GlyTech Inc Acromegaly Drug Details

16.2.1 Drug Snapshot

16.2.1.1 Originator

16.2.1.2 Collaborator/Co-Developer

- 16.2.1.3 Route of Administration
- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. IONIS PHARMACEUTICALS INC ACROMEGALY PIPELINE DETAILS

- 17.1 Ionis Pharmaceuticals Inc Business Profile
- 17.2 Ionis Pharmaceuticals Inc Acromegaly Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. ITALFARMACO SPA ACROMEGALY PIPELINE DETAILS

- 18.1 Italfarmaco SpA Business Profile
- 18.2 Italfarmaco SpA Acromegaly Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status

- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. MIDATECH PHARMA PLC ACROMEGALY PIPELINE DETAILS

- 19.1 Midatech Pharma Plc Business Profile
- 19.2 Midatech Pharma Plc Acromegaly Drug Details
 - 19.2.1 Drug Snapshot
 - 19.2.1.1 Originator
 - 19.2.1.2 Collaborator/Co-Developer
 - 19.2.1.3 Route of Administration
 - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 19.2.1.5 Area
 - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20. ONO PHARMACEUTICAL CO LTD ACROMEGALY PIPELINE DETAILS

- 20.1 Ono Pharmaceutical Co Ltd Business Profile
- 20.2 Ono Pharmaceutical Co Ltd Acromegaly Drug Details
 - 20.2.1 Drug Snapshot
 - 20.2.1.1 Originator
 - 20.2.1.2 Collaborator/Co-Developer
 - 20.2.1.3 Route of Administration
 - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 20.2.1.5 Area
 - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21. STRONGBRIDGE BIOPHARMA PLC ACROMEGALY PIPELINE DETAILS

- 21.1 Strongbridge Biopharma plc Business Profile
- 21.2 Strongbridge Biopharma plc Acromegaly Drug Details
 - 21.2.1 Drug Snapshot
 - 21.2.1.1 Originator
 - 21.2.1.2 Collaborator/Co-Developer
 - 21.2.1.3 Route of Administration
 - 21.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 21.2.1.5 Area
 - 21.2.1.6 Type of Molecular Entity
- 21.3 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

20. LATEST ACROMEGALY DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information

I would like to order

Product name: 2019 Future of Acromegaly R&D Pipeline Drugs and Companies- Analysis of Global Acromegaly Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2A120E4A4C0EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2A120E4A4C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970